FRNM NASDAQ
Freenome, Inc.
1W: -15.0%
1M: +24.4%
YTD: +25.0%
$14.37
-0.42 (-2.84%)
Weekly Expected Move ±9.2%
$12
$13
$14
$16
$17
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$117.2M
52W Range9.95-17.175
Volume535,433
Avg Volume643,201
Beta0.35
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOAaron Elliott
Employees378
SectorHealthcare
IndustryBiotechnology
IPO Date2026-07-21
Websitefreenome.com
3300 Marina Boulevard
Brisbane, CA 94005
US
Brisbane, CA 94005
US
About Freenome, Inc.
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.S. Food and Drug Administration (FDA).
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Elliott Aaron Matthe | F-InKind | 71,920 | $15.25 | 2026-09-02 |
| Waksal Harlan | C-Conversion | 30,000 | — | 2026-07-20 |
| Waksal Harlan | C-Conversion | 30,000 | — | 2026-07-20 |
| Nuechterlein Carole | 0 | — | 2026-07-20 | |
| Costello Ann Catheri | 0 | — | 2026-07-20 |